Drug development today needs to balance agility, speed, and risk in defining probability of success for molecules, mechanisms, and therapeutic concepts. New techniques such as fMRI promise to be part of a sequence that could transform drug development. Although numerous review articles exist that discuss the use of imaging in drug development, no one source is available that combines the various techniques and includes a discussion of disease mapping. Imaging in CNS Drug Discovery and Development, Implications for Disease and Therapy will serve to distill the most salient developments in the use of imaging in drug development and disease mapping. It will launch evolving concepts that integrate new imaging technologies and paradigms with molecular medicine and molecular profiling (qmonicsq) as well as consider the ethical issues that arise as a result of disease or state diagnosis and the use of imaging in the public eye.... CNS requires the temporary suspension of the physiological role of the BBB to bar larger molecules from the CNS. ... 2004; Ford et al. ... (a) Diagram and protocol for BBB opening used in this experiment. ... 2006 The National Academy of Sciences of the USA In Vivo Mouse Imaging and Spectroscopy in Drug Discovery aanbsp;...
|Title||:||Imaging in CNS Drug Discovery and Development|
|Author||:||David Borsook, Lino R. Beccera, Edward Bullmore, Richard J. Hargreaves|
|Publisher||:||Springer Science & Business Media - 2010-03-10|